Male Hypogonadism Market Research, 2030

The global male hypogonadism market size was $3.1 billion in 2020, and is projected to reach $5.1 billion by 2030, growing at a CAGR of 5.1% from 2021 to 2030. Male hypogonadism is a medical disorder in which the testes do not produce enough testosterone, resulting in a lack of muscle mass development, impaired body hair growth, development of breast tissues, and lack of voice deepening. It is the outcome of testicular issue or disorder that affects the hypothalamus and pituitary gland. Hypogonadism affects various organs and one's quality of life. The indications and symptoms of the deficiency vary depending on when it was initially developed, severity of the deficiency, and whether or not the primary functions of the testes are impacted.

[COVIDIMPACTSTATEMENT]

Get more information on this report : Request Sample Pages

Male hypogonadism market trends include rise in prevalence and incidence of testosterone deficiency in males, increase in infertility rates, and surge in awareness of male hypogonadism treatment choices among the patient population drive the growth of the male hypogonadism market. Furthermore, risk of getting affected by hypogonadism is very high in the geriatric population as well as in the population suffering with obesity and diabetes. Thus, growth in geriatric population and rise in incidence of chronic lifestyle disorders, including obesity and diabetes drive male hypogonadism market growth. However, testosterone replacement treatment (TRT) hampers male hypogonadism industry, owing to severe adverse after effects of external testosterone hormone injection. Conversely, technological developments are expected to create new male hypogonadism market opportunity for growth during the forecast period. Thus, male hypogonadism market forecast looks promising owing to aforementioned growth factors.

Market Segmentation 

The global male hypogonadism market is segmented on the basis of therapy, drug delivery and type. Depending on therapy, it is categorized into testosterone replacement therapy and gonadotropin & gonadotropin-releasing hormones therapy. The gonadotropin & gonadotropin-releasing hormones therapy segment is categorized into luteinizing hormone (LH), follicle-stimulating hormone (FSH), human chorionic gonadotropin (HCG), and gonadotropin-releasing hormone (GNRH). According to drug delivery, it is fragmented into topical gels, injectable, transdermal patches, and others. As per type, it is segregated into Klinefelter’s syndrome, Kallmann syndrome, pituitary disorders, and others. Region wise, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Depending on therapy, testosterone replacement therapy held largest male hypogonadism market share in 2020 while Gonadotropin and Gonadotropin Releasing Hormone Therapy is anticipated to be the fastest growing segment in the forecast period

[THERAPYGRAPH]

According to drug delivery, topical gels segment dominated the market in 2020 owing to rise in prescription of topical gels compared to other dosage forms. Moreover, transdermal patches segment is anticipated to be the fastest growing segment with a CAGR

[DRUGDELIVERYGRAPH]

As per the type, pituitary disorder segment dominated the market in 2020 and is also expected to grow at highest CAGR of 5.8% during the forecast period. The growth of pituitary disorder segment is owing to surge in genetic disorders in aging population

[TYPEGRAPH]

Region wise, North America dominated the market 2020 owing to increase in awareness campaigns of men healthcare and surge in primary and secondary hypogonadism cases. Asia-Pacific is anticipated to be the fastest growing segment with a CAGR of 7.9%, owing to the increase in number of people with medical expertise and surge in awareness schemes and campaigns for health of men.

[REGIONGRAPH]

Major key players operating in the global male hypogonadism market are Allergan PLC., Bayer AG, Eli Lily & Company, Endo Iternational PLC., Ferring Holdings SA, Finox Biotech, Merck & Co. Inc., Pfizer, Perrigo Company PLC., Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the male hypogonadism market analysis from 2020 to 2030 to identify the prevailing male hypogonadism market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the male hypogonadism market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global male hypogonadism market trends, key players, market segments, application areas, and market growth strategies.

 Key Market Segments

• By Type
  • Klinefelters Syndrome
  • Kallmann Syndrome
  • Pituitary Disorders
  • Others
• By Drug Delivery
  • Topical Gels
  • Injectables
  • Transdermal Patches
  • Others
• By Therapy
  • Testosterone Replacement Therapy
  • Gonadotropin and Gonadotropin Releasing Hormone Therapy
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Rest of Europe
  • Asia-Pacific
    • India
    • Rest of Asia-Pacific
    • Japan
    • China
  • LAMEA
    • Latin America
    • Middle East
    • Africa

 
Key Market Players

• Endo International plc.
• Perrigo Company plc
• Merck & Co., Inc.
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Eli Lilly and Company Ltd.
• Ferring
• Finox Biotec
• Allergan plc
• Bayer AG

• CHAPTER 1:INTRODUCTION

  • 1.1.Report description

  • 1.2.Key market segments

  • 1.3.Key benefits to the stakeholders

  • 1.4.Research Methodology

    • 1.4.1.Secondary research

    • 1.4.2.Primary research

    • 1.4.3.Analyst tools and models

• CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study

  • 2.2.CXO Perspective

• CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope

  • 3.2.Key findings

    • 3.2.1.Top investment pockets

  • 3.3.Porter’s five forces analysis

  • 3.4.Top player positioning

  • 3.5.Market dynamics

    • 3.5.1.Drivers

    • 3.5.2.Restraints

    • 3.5.3.Opportunities

  • 3.6.COVID-19 Impact Analysis on the market

• CHAPTER 4: MALE HYPOGONADISM MARKET, BY DRUG DELIVERY

  • 4.1 Overview

  • 4.1.1 Market size and forecast

  • 4.2 Topical Gels

    • 4.2.1 Key market trends, growth factors and opportunities

    • 4.2.2 Market size and forecast, by region

    • 4.2.3 Market analysis by country

  • 4.3 Injectables

    • 4.3.1 Key market trends, growth factors and opportunities

    • 4.3.2 Market size and forecast, by region

    • 4.3.3 Market analysis by country

  • 4.4 Transdermal Patches

    • 4.4.1 Key market trends, growth factors and opportunities

    • 4.4.2 Market size and forecast, by region

    • 4.4.3 Market analysis by country

  • 4.5 Others

    • 4.5.1 Key market trends, growth factors and opportunities

    • 4.5.2 Market size and forecast, by region

    • 4.5.3 Market analysis by country

• CHAPTER 5: MALE HYPOGONADISM MARKET, BY THERAPY

  • 5.1 Overview

  • 5.1.1 Market size and forecast

  • 5.2 Testosterone Replacement Therapy

    • 5.2.1 Key market trends, growth factors and opportunities

    • 5.2.2 Market size and forecast, by region

    • 5.2.3 Market analysis by country

  • 5.3 Gonadotropin and Gonadotropin Releasing Hormone Therapy

    • 5.3.1 Key market trends, growth factors and opportunities

    • 5.3.2 Market size and forecast, by region

    • 5.3.3 Market analysis by country

• CHAPTER 6: MALE HYPOGONADISM MARKET, BY TYPE

  • 6.1 Overview

  • 6.1.1 Market size and forecast

  • 6.2 Klinefelters Syndrome

    • 6.2.1 Key market trends, growth factors and opportunities

    • 6.2.2 Market size and forecast, by region

    • 6.2.3 Market analysis by country

  • 6.3 Kallmann Syndrome

    • 6.3.1 Key market trends, growth factors and opportunities

    • 6.3.2 Market size and forecast, by region

    • 6.3.3 Market analysis by country

  • 6.4 Pituitary Disorders

    • 6.4.1 Key market trends, growth factors and opportunities

    • 6.4.2 Market size and forecast, by region

    • 6.4.3 Market analysis by country

  • 6.5 Others

    • 6.5.1 Key market trends, growth factors and opportunities

    • 6.5.2 Market size and forecast, by region

    • 6.5.3 Market analysis by country

• CHAPTER 7: MALE HYPOGONADISM MARKET, BY REGION

  • 7.1 Overview

  • 7.1.1 Market size and forecast

  • 7.2 North America

    • 7.2.1 Key trends and opportunities

    • 7.2.2 North America Market size and forecast, by Drug Delivery

    • 7.2.3 North America Market size and forecast, by Therapy

    • 7.2.4 North America Market size and forecast, by Type

    • 7.2.5 North America Market size and forecast, by country

      • 7.2.5.1 U.S.

      • 7.2.5.1.1 Market size and forecast, by Drug Delivery
      • 7.2.5.1.2 Market size and forecast, by Therapy
      • 7.2.5.1.3 Market size and forecast, by Type

      • 7.2.5.2 Canada

      • 7.2.5.2.1 Market size and forecast, by Drug Delivery
      • 7.2.5.2.2 Market size and forecast, by Therapy
      • 7.2.5.2.3 Market size and forecast, by Type

      • 7.2.5.3 Mexico

      • 7.2.5.3.1 Market size and forecast, by Drug Delivery
      • 7.2.5.3.2 Market size and forecast, by Therapy
      • 7.2.5.3.3 Market size and forecast, by Type

  • 7.3 Europe

    • 7.3.1 Key trends and opportunities

    • 7.3.2 Europe Market size and forecast, by Drug Delivery

    • 7.3.3 Europe Market size and forecast, by Therapy

    • 7.3.4 Europe Market size and forecast, by Type

    • 7.3.5 Europe Market size and forecast, by country

      • 7.3.5.1 Germany

      • 7.3.5.1.1 Market size and forecast, by Drug Delivery
      • 7.3.5.1.2 Market size and forecast, by Therapy
      • 7.3.5.1.3 Market size and forecast, by Type

      • 7.3.5.2 France

      • 7.3.5.2.1 Market size and forecast, by Drug Delivery
      • 7.3.5.2.2 Market size and forecast, by Therapy
      • 7.3.5.2.3 Market size and forecast, by Type

      • 7.3.5.3 U.K.

      • 7.3.5.3.1 Market size and forecast, by Drug Delivery
      • 7.3.5.3.2 Market size and forecast, by Therapy
      • 7.3.5.3.3 Market size and forecast, by Type

      • 7.3.5.4 Rest of Europe

      • 7.3.5.4.1 Market size and forecast, by Drug Delivery
      • 7.3.5.4.2 Market size and forecast, by Therapy
      • 7.3.5.4.3 Market size and forecast, by Type

  • 7.4 Asia-Pacific

    • 7.4.1 Key trends and opportunities

    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Delivery

    • 7.4.3 Asia-Pacific Market size and forecast, by Therapy

    • 7.4.4 Asia-Pacific Market size and forecast, by Type

    • 7.4.5 Asia-Pacific Market size and forecast, by country

      • 7.4.5.1 Japan

      • 7.4.5.1.1 Market size and forecast, by Drug Delivery
      • 7.4.5.1.2 Market size and forecast, by Therapy
      • 7.4.5.1.3 Market size and forecast, by Type

      • 7.4.5.2 China

      • 7.4.5.2.1 Market size and forecast, by Drug Delivery
      • 7.4.5.2.2 Market size and forecast, by Therapy
      • 7.4.5.2.3 Market size and forecast, by Type

      • 7.4.5.3 India

      • 7.4.5.3.1 Market size and forecast, by Drug Delivery
      • 7.4.5.3.2 Market size and forecast, by Therapy
      • 7.4.5.3.3 Market size and forecast, by Type

      • 7.4.5.4 Rest of Asia-Pacific

      • 7.4.5.4.1 Market size and forecast, by Drug Delivery
      • 7.4.5.4.2 Market size and forecast, by Therapy
      • 7.4.5.4.3 Market size and forecast, by Type

  • 7.5 LAMEA

    • 7.5.1 Key trends and opportunities

    • 7.5.2 LAMEA Market size and forecast, by Drug Delivery

    • 7.5.3 LAMEA Market size and forecast, by Therapy

    • 7.5.4 LAMEA Market size and forecast, by Type

    • 7.5.5 LAMEA Market size and forecast, by country

      • 7.5.5.1 Latin America

      • 7.5.5.1.1 Market size and forecast, by Drug Delivery
      • 7.5.5.1.2 Market size and forecast, by Therapy
      • 7.5.5.1.3 Market size and forecast, by Type

      • 7.5.5.2 Middle East

      • 7.5.5.2.1 Market size and forecast, by Drug Delivery
      • 7.5.5.2.2 Market size and forecast, by Therapy
      • 7.5.5.2.3 Market size and forecast, by Type

      • 7.5.5.3 Africa

      • 7.5.5.3.1 Market size and forecast, by Drug Delivery
      • 7.5.5.3.2 Market size and forecast, by Therapy
      • 7.5.5.3.3 Market size and forecast, by Type

• CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction

  • 8.2. Top winning strategies

  • 8.3. Product Mapping of Top 10 Player

  • 8.4. Competitive Dashboard

  • 8.5. Competitive Heatmap

  • 8.6. Key developments

• CHAPTER 9: COMPANY PROFILES

  • 9.1 Allergan plc

    • 9.1.1 Company overview

    • 9.1.2 Company snapshot

    • 9.1.3 Operating business segments

    • 9.1.4 Product portfolio

    • 9.1.5 Business performance

    • 9.1.6 Key strategic moves and developments

  • 9.2 Pfizer Inc.

    • 9.2.1 Company overview

    • 9.2.2 Company snapshot

    • 9.2.3 Operating business segments

    • 9.2.4 Product portfolio

    • 9.2.5 Business performance

    • 9.2.6 Key strategic moves and developments

  • 9.3 Bayer AG

    • 9.3.1 Company overview

    • 9.3.2 Company snapshot

    • 9.3.3 Operating business segments

    • 9.3.4 Product portfolio

    • 9.3.5 Business performance

    • 9.3.6 Key strategic moves and developments

  • 9.4 Eli Lilly and Company Ltd.

    • 9.4.1 Company overview

    • 9.4.2 Company snapshot

    • 9.4.3 Operating business segments

    • 9.4.4 Product portfolio

    • 9.4.5 Business performance

    • 9.4.6 Key strategic moves and developments

  • 9.5 Endo International plc.

    • 9.5.1 Company overview

    • 9.5.2 Company snapshot

    • 9.5.3 Operating business segments

    • 9.5.4 Product portfolio

    • 9.5.5 Business performance

    • 9.5.6 Key strategic moves and developments

  • 9.6 Merck & Co., Inc.

    • 9.6.1 Company overview

    • 9.6.2 Company snapshot

    • 9.6.3 Operating business segments

    • 9.6.4 Product portfolio

    • 9.6.5 Business performance

    • 9.6.6 Key strategic moves and developments

  • 9.7 Ferring

    • 9.7.1 Company overview

    • 9.7.2 Company snapshot

    • 9.7.3 Operating business segments

    • 9.7.4 Product portfolio

    • 9.7.5 Business performance

    • 9.7.6 Key strategic moves and developments

  • 9.8 Finox Biotec

    • 9.8.1 Company overview

    • 9.8.2 Company snapshot

    • 9.8.3 Operating business segments

    • 9.8.4 Product portfolio

    • 9.8.5 Business performance

    • 9.8.6 Key strategic moves and developments

  • 9.9 Teva Pharmaceutical Industries Ltd.

    • 9.9.1 Company overview

    • 9.9.2 Company snapshot

    • 9.9.3 Operating business segments

    • 9.9.4 Product portfolio

    • 9.9.5 Business performance

    • 9.9.6 Key strategic moves and developments

  • 9.10 Perrigo Company plc

    • 9.10.1 Company overview

    • 9.10.2 Company snapshot

    • 9.10.3 Operating business segments

    • 9.10.4 Product portfolio

    • 9.10.5 Business performance

    • 9.10.6 Key strategic moves and developments

• LIST OF TABLES

• TABLE 1. GLOBAL MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
  TABLE 2. MALE HYPOGONADISM MARKET REVENUE, FOR TOPICAL GELS, BY REGION , 2020-2030,($MILLION)
  TABLE 3. MALE HYPOGONADISM MARKET TOPICAL GELS BY COUNTRY, 2020-2030,($MILLION)
  TABLE 4. MALE HYPOGONADISM MARKET REVENUE, FOR INJECTABLES, BY REGION , 2020-2030,($MILLION)
  TABLE 5. MALE HYPOGONADISM MARKET INJECTABLES BY COUNTRY, 2020-2030,($MILLION)
  TABLE 6. MALE HYPOGONADISM MARKET REVENUE, FOR TRANSDERMAL PATCHES, BY REGION , 2020-2030,($MILLION)
  TABLE 7. MALE HYPOGONADISM MARKET TRANSDERMAL PATCHES BY COUNTRY, 2020-2030,($MILLION)
  TABLE 8. MALE HYPOGONADISM MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
  TABLE 9. MALE HYPOGONADISM MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
  TABLE 10. GLOBAL MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
  TABLE 11. MALE HYPOGONADISM MARKET REVENUE, FOR TESTOSTERONE REPLACEMENT THERAPY, BY REGION , 2020-2030,($MILLION)
  TABLE 12. MALE HYPOGONADISM MARKET TESTOSTERONE REPLACEMENT THERAPY BY COUNTRY, 2020-2030,($MILLION)
  TABLE 13. MALE HYPOGONADISM MARKET REVENUE, FOR GONADOTROPIN AND GONADOTROPIN RELEASING HORMONE THERAPY, BY REGION , 2020-2030,($MILLION)
  TABLE 14. MALE HYPOGONADISM MARKET GONADOTROPIN AND GONADOTROPIN RELEASING HORMONE THERAPY BY COUNTRY, 2020-2030,($MILLION)
  TABLE 15. GLOBAL MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
  TABLE 16. MALE HYPOGONADISM MARKET REVENUE, FOR KLINEFELTERS SYNDROME, BY REGION , 2020-2030,($MILLION)
  TABLE 17. MALE HYPOGONADISM MARKET KLINEFELTERS SYNDROME BY COUNTRY, 2020-2030,($MILLION)
  TABLE 18. MALE HYPOGONADISM MARKET REVENUE, FOR KALLMANN SYNDROME, BY REGION , 2020-2030,($MILLION)
  TABLE 19. MALE HYPOGONADISM MARKET KALLMANN SYNDROME BY COUNTRY, 2020-2030,($MILLION)
  TABLE 20. MALE HYPOGONADISM MARKET REVENUE, FOR PITUITARY DISORDERS, BY REGION , 2020-2030,($MILLION)
  TABLE 21. MALE HYPOGONADISM MARKET PITUITARY DISORDERS BY COUNTRY, 2020-2030,($MILLION)
  TABLE 22. MALE HYPOGONADISM MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
  TABLE 23. MALE HYPOGONADISM MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
  TABLE 24. MALE HYPOGONADISM MARKET, BY REGION, 2020-2030,($MILLION)
  TABLE 25. NORTH AMERICA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
  TABLE 26. NORTH AMERICA MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
  TABLE 27. NORTH AMERICA MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
  TABLE 28. NORTH AMERICA MALE HYPOGONADISM MARKET, BY COUNTRY, 2020-2030,($MILLION)
  TABLE 29. U.S. MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 30. U.S. MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 31. U.S. MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 32. CANADA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 33. CANADA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 34. CANADA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 35. MEXICO MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 36. MEXICO MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 37. MEXICO MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 38. EUROPE MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
  TABLE 39. EUROPE MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
  TABLE 40. EUROPE MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
  TABLE 41. EUROPE MALE HYPOGONADISM MARKET, BY COUNTRY, 2020-2030,($MILLION)
  TABLE 42. GERMANY MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 43. GERMANY MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 44. GERMANY MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 45. FRANCE MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 46. FRANCE MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 47. FRANCE MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 48. U.K. MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 49. U.K. MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 50. U.K. MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 51. REST OF EUROPE MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 52. REST OF EUROPE MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 53. REST OF EUROPE MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 54. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
  TABLE 55. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
  TABLE 56. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
  TABLE 57. ASIA-PACIFIC MALE HYPOGONADISM MARKET, BY COUNTRY, 2020-2030,($MILLION)
  TABLE 58. JAPAN MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 59. JAPAN MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 60. JAPAN MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 61. CHINA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 62. CHINA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 63. CHINA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 64. INDIA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 65. INDIA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 66. INDIA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 67. REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 68. REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 69. REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 70. LAMEA MALE HYPOGONADISM MARKET, BY DRUG DELIVERY, 2020-2030,($MILLION)
  TABLE 71. LAMEA MALE HYPOGONADISM MARKET, BY THERAPY, 2020-2030,($MILLION)
  TABLE 72. LAMEA MALE HYPOGONADISM MARKET, BY TYPE, 2020-2030,($MILLION)
  TABLE 73. LAMEA MALE HYPOGONADISM MARKET, BY COUNTRY, 2020-2030,($MILLION)
  TABLE 74. LATIN AMERICA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 75. LATIN AMERICA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 76. LATIN AMERICA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 77. MIDDLE EAST MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 78. MIDDLE EAST MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 79. MIDDLE EAST MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 80. AFRICA MALE HYPOGONADISM MARKET BY DRUG DELIVERY 2020-2030,($MILLION)
  TABLE 81. AFRICA MALE HYPOGONADISM MARKET BY THERAPY 2020-2030,($MILLION)
  TABLE 82. AFRICA MALE HYPOGONADISM MARKET BY TYPE 2020-2030,($MILLION)
  TABLE 83.ALLERGAN PLC: COMPANY SNAPSHOT
  TABLE 84.ALLERGAN PLC: OPERATING SEGMENTS
  TABLE 85.ALLERGAN PLC: PRODUCT PORTFOLIO
  TABLE 86.ALLERGAN PLC: NET SALES,
  TABLE 87.ALLERGAN PLC: KEY STRATERGIES
  TABLE 88.PFIZER INC.: COMPANY SNAPSHOT
  TABLE 89.PFIZER INC.: OPERATING SEGMENTS
  TABLE 90.PFIZER INC.: PRODUCT PORTFOLIO
  TABLE 91.PFIZER INC.: NET SALES,
  TABLE 92.PFIZER INC.: KEY STRATERGIES
  TABLE 93.BAYER AG: COMPANY SNAPSHOT
  TABLE 94.BAYER AG: OPERATING SEGMENTS
  TABLE 95.BAYER AG: PRODUCT PORTFOLIO
  TABLE 96.BAYER AG: NET SALES,
  TABLE 97.BAYER AG: KEY STRATERGIES
  TABLE 98.ELI LILLY AND COMPANY LTD.: COMPANY SNAPSHOT
  TABLE 99.ELI LILLY AND COMPANY LTD.: OPERATING SEGMENTS
  TABLE 100.ELI LILLY AND COMPANY LTD.: PRODUCT PORTFOLIO
  TABLE 101.ELI LILLY AND COMPANY LTD.: NET SALES,
  TABLE 102.ELI LILLY AND COMPANY LTD.: KEY STRATERGIES
  TABLE 103.ENDO INTERNATIONAL PLC.: COMPANY SNAPSHOT
  TABLE 104.ENDO INTERNATIONAL PLC.: OPERATING SEGMENTS
  TABLE 105.ENDO INTERNATIONAL PLC.: PRODUCT PORTFOLIO
  TABLE 106.ENDO INTERNATIONAL PLC.: NET SALES,
  TABLE 107.ENDO INTERNATIONAL PLC.: KEY STRATERGIES
  TABLE 108.MERCK & CO., INC.: COMPANY SNAPSHOT
  TABLE 109.MERCK & CO., INC.: OPERATING SEGMENTS
  TABLE 110.MERCK & CO., INC.: PRODUCT PORTFOLIO
  TABLE 111.MERCK & CO., INC.: NET SALES,
  TABLE 112.MERCK & CO., INC.: KEY STRATERGIES
  TABLE 113.FERRING: COMPANY SNAPSHOT
  TABLE 114.FERRING: OPERATING SEGMENTS
  TABLE 115.FERRING: PRODUCT PORTFOLIO
  TABLE 116.FERRING: NET SALES,
  TABLE 117.FERRING: KEY STRATERGIES
  TABLE 118.FINOX BIOTEC: COMPANY SNAPSHOT
  TABLE 119.FINOX BIOTEC: OPERATING SEGMENTS
  TABLE 120.FINOX BIOTEC: PRODUCT PORTFOLIO
  TABLE 121.FINOX BIOTEC: NET SALES,
  TABLE 122.FINOX BIOTEC: KEY STRATERGIES
  TABLE 123.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  TABLE 124.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  TABLE 125.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  TABLE 126.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
  TABLE 127.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  TABLE 128.PERRIGO COMPANY PLC: COMPANY SNAPSHOT
  TABLE 129.PERRIGO COMPANY PLC: OPERATING SEGMENTS
  TABLE 130.PERRIGO COMPANY PLC: PRODUCT PORTFOLIO
  TABLE 131.PERRIGO COMPANY PLC: NET SALES,
  TABLE 132.PERRIGO COMPANY PLC: KEY STRATERGIES

• LIST OF FIGURES

• FIGURE 1.MALE HYPOGONADISM MARKET SEGMENTATION
  FIGURE 2.MALE HYPOGONADISM MARKET,2020-2030
  FIGURE 3.MALE HYPOGONADISM MARKET,2020-2030
  FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  FIGURE 5.PORTER FIVE-1
  FIGURE 6.PORTER FIVE-2
  FIGURE 7.PORTER FIVE-3
  FIGURE 8.PORTER FIVE-4
  FIGURE 9.PORTER FIVE-5
  FIGURE 10.TOP PLAYER POSITIONING
  FIGURE 11.MALE HYPOGONADISM MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  FIGURE 12.MALE HYPOGONADISM MARKET,BY DRUG DELIVERY,2020(%)
  FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TOPICAL GELS MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 14.COMPARATIVE SHARE ANALYSIS OF INJECTABLES MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 15.COMPARATIVE SHARE ANALYSIS OF TRANSDERMAL PATCHES MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 17.MALE HYPOGONADISM MARKET,BY THERAPY,2020(%)
  FIGURE 18.COMPARATIVE SHARE ANALYSIS OF TESTOSTERONE REPLACEMENT THERAPY MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GONADOTROPIN AND GONADOTROPIN RELEASING HORMONE THERAPY MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 20.MALE HYPOGONADISM MARKET,BY TYPE,2020(%)
  FIGURE 21.COMPARATIVE SHARE ANALYSIS OF KLINEFELTERS SYNDROME MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 22.COMPARATIVE SHARE ANALYSIS OF KALLMANN SYNDROME MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 23.COMPARATIVE SHARE ANALYSIS OF PITUITARY DISORDERS MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 24.COMPARATIVE SHARE ANALYSIS OF OTHERS MALE HYPOGONADISM MARKET,2020-2030(%)
  FIGURE 25.MALE HYPOGONADISM MARKET BY REGION,2020
  FIGURE 26.U.S. MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 27.CANADA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 28.MEXICO MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 29.GERMANY MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 30.FRANCE MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 31.U.K. MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 32.REST OF EUROPE MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 33.JAPAN MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 34.CHINA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 35.INDIA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 36.REST OF ASIA-PACIFIC MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 37.LATIN AMERICA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 38.MIDDLE EAST MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 39.AFRICA MALE HYPOGONADISM MARKET,2020-2030($MILLION)
  FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
  FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
  FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
  FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS
  FIGURE 44.COMPETITIVE DASHBOARD
  FIGURE 45.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  FIGURE 46.ALLERGAN PLC.: NET SALES ,($MILLION)
  FIGURE 47.PFIZER INC..: NET SALES ,($MILLION)
  FIGURE 48.BAYER AG.: NET SALES ,($MILLION)
  FIGURE 49.ELI LILLY AND COMPANY LTD..: NET SALES ,($MILLION)
  FIGURE 50.ENDO INTERNATIONAL PLC..: NET SALES ,($MILLION)
  FIGURE 51.MERCK & CO., INC..: NET SALES ,($MILLION)
  FIGURE 52.FERRING.: NET SALES ,($MILLION)
  FIGURE 53.FINOX BIOTEC.: NET SALES ,($MILLION)
  FIGURE 54.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)
  FIGURE 55.PERRIGO COMPANY PLC.: NET SALES ,($MILLION)